ArticlePharmacological reports : PR2026
WIN55,212-2 attenuates intestinal fibrosis in a DSS-induced mouse model.
Article in Pharmacological reports : PR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundInflammatory bowel diseases (IBD) are often associated with intestinal fibrosis. There is increased interest in new methods for managing intestinal fibrosis, among which the endocannabinoid system (ECS) is an interesting therapeutic target. The primary purpose of the study was to evaluate the effect of CB1/2 agonist, WIN 55,212-2 (WIN) on expression of fibrosis regulatory proteins: alpha smooth muscle Actin 2 (ACTA2), Collagen I (COLIA1), Fibronectin 1 (FN1) and SMAD family member 3 (SMAD3) in a mice model of dextran sulfate sodium (DSS)-induced intestinal fibrosis.
methodsChronic intestinal fibrosis was induced by oral administration of 1.5% DSS in rotation with tap water for 3 weeks in three cycles. WIN was administered intraperitoneally, once daily starting from day 10th and continued every other day until day 77th. The expression of genes encoding ACTA2, COL1A1, FN1, SMAD3, Col1a1, Fn1 both in mouse and human colon, was assessed with real-time PCR.
resultsWe found lower relative expression of genes encoding fibrosis regulatory proteins in colonic mucosa of mice treated with WIN than in inflamed mice: ACTA2 (–51%), COL1A1 (–44%), FN1 (–60%), and SMAD3 (–22%). Human colonic mucosal patients with UC showed higher expression of COL1A1 (+ 57%) and SMAD3 (+ 34%) compared to healthy controls.
conclusionsOur results show that regulation of ECS activity may play a role in the inhibition of intestinal fibrosis in IBD and appears as a potential therapeutic target in patients at high risk of developing strictures.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.